Obesity is defined by excessive
body fat and higher body mass index. The average BMI index for obesity is above
30 (obese). Obesity is one of the most prevalent disease conditions across the
world, and it is prevalent in developed, emerging, and undeveloped regions.
Surgeries that aid in the treatment of obesity include, gastric bypass,
adjustable gastric banding, gastric sleeve, duodenal switch, and intragastric
balloon treatment.
Statistics:
The global obesity
management drugs market is estimated to account for US$ 764.7 Mn in terms
of value in 2020 and is expected to reach US$ 1,078.9 Mn by the end of 2027.
Global Obesity Management Market:
Drivers
R&D of new products is
expected to propel growth of the global obesity management market over the
forecast period. For instance, in May 2019, VIVUS, Inc., a biopharmaceutical
company, announced the commencement of phase IV safety and efficacy Qsymia for
weight management in obese patients.
Global Obesity Management Market:
Opportunities
Adoption of novel technologies in
treatment of obesity is expected to offer lucrative growth opportunities for
players in the global obesity management market. For instance, in August 2020,
researchers from Harvard University reported use of CRISPR-Cas9 gene-editing
technology to engineer human white fat so that it displays the properties of
brown fat.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2824
Global Obesity Management Market:
Restraints
Side effects and safety
controversies is expected to hinder growth of the global obesity management
market. Though the number of obesity drug users are rapidly increasing due to
their many benefits, studies show that there are certain side effects and
adverse health effects of obesity drugs over long term that include, high
cholesterol, diabetes, high blood pressure, heart diseases, strokes, sleep
apnea, depression, asthma, and cancer.
Key Takeaways:
The global obesity management
drugs market was valued at US$ 729.9 Mn in 2019 and is forecast to reach a
value of US$ 1,078.9 Mn by 2027 at a CAGR of 5.0% between 2020 and 2027. Major
factor driving the growth of global obesity management drugs market during the
forecast period include increasing prevalence of obesity, and number of
products available.
Orlistat held dominant position
in the global obesity management drugs market in 2019, accounting for 31.9%
share in terms of value, followed by Liraglutide and Lorcaserin, respectively.
Market Trends
Major players in the global
obesity management market are focused on adopting collaboration and partnership
strategies to expand their product portfolio. For instance, on June 2019,
NovoFit, a global distributor for fitness equipment, entered a strategic
partnership with Amer Sports’ leading fitness brand, Precor for product
distributorship in Australia. The partnership is projected to increase market
positioning of NovaFit and Amer Sports in Australia.
Possible link of obesity with
cancer is expected to propel growth of the global obesity management market.
For instance, in September 2020, a research at Washington University School of
Medicine in the U.S. reported that for every 5kg of weight gained the risk of
the cancer increases by 5%.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/anti-obesity-drugs-market-2824
Regulations
U.S
The 505(b)(2) regulation offers a
less expensive and faster new drug development pathway. 505 (b)(2) was added to
FD&C act by Drug Price Competition and Patent Term Restoration Act of 1984
(Hatch-Waxman act).
When the generic company files
ANDA with Paragraph IV certification, the first applicant to submit
substantially completed ANDA is given 180 days market exclusivity under para IV
of Hatch-Waxman act
In October 1999, U. S. Department
of Health and Human Services Food and Drug Administration published a draft
guidance for applications covered by section 505 (b)(2)
Global Obesity Management Market:
Competitive Landscape
Major players operating in the
global obesity management market include, F Hoffmann La Roche Ltd.,
GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc.,
VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.
Global Obesity Management Market:
Key Developments
Major players in the global
obesity management market are focused on adopting collaboration and partnership
strategies to expand their product portfolio. For instance, in July 2018, Eisai
Co., Ltd. entered an agreement to grant exclusive development and marketing
rights to CY Biotech for its anti-obesity agent lorcaserin hydrochloride
(lorcaserin) in China.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2824
About Coherent
Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment